文献速递肝病

非酒精性脂肪性肝炎随机试验中安慰剂反应的简明解读

The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-06-04

该研究通过概率模拟(每项模拟试验120名受试者)量化非酒精性脂肪性肝炎(NASH)试验中安慰剂反应的影响因素。大型IIb/III期试验中22%的安慰剂治疗受试者纤维化改善至少1期,模拟显示80%试验的安慰剂反应率在15%-30%之间,与已报告试验一致。肝脏活检相关因素大多不可修改,安慰剂反应率的变异性挑战了活检在试验终点评估中的作用。

要点

  • NASH试验中22%安慰剂治疗者纤维化改善至少1期。
  • 模拟显示80%试验的安慰剂反应率在15%-30%之间。
  • 活检采样和观察者变异等因素贡献安慰剂反应,且大多不可修改。

核心结论

  • NASH试验中安慰剂反应可由采样和观察者变异、均值回归及纤维化进展解释。
  • 活检相关因素大多不可修改,安慰剂反应率的变异性挑战活检作为试验终点的作用。

研究设计与样本

  • 采用概率模拟,每项模拟试验纳入120名受试者。
  • 模型参数包括采样和观察者变异、均值回归及校准至已报告试验结果的净纤维化进展。

主要发现

  • 大型IIb和III期试验中,22%的基线纤维化2或3期NASH安慰剂治疗受试者改善至少1期,且净疾病进展极小。
  • 同时活检研究估计采样和观察者变异显示明显纤维化改善比恶化更可能。
  • 净纤维化进展估计为每年0.05期;模拟安慰剂反应率为22%,80%试验在15%至30%之间。
  • 观察者变异进一步增加可进一步提高安慰剂反应。

关键数值与推荐

  • 22%的安慰剂治疗受试者纤维化改善至少1期。
  • 模拟安慰剂反应率22%,80%试验在15%至30%之间。
  • 净纤维化进展估计为每年0.05期。

临床怎么用

  • 解读NASH试验结果时需考虑安慰剂反应率及其变异。
  • 活检相关变异影响终点评估,提示需关注试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver histology is the primary endpoint in phase III trials in nonalcoholic steatohepatitis (NASH). There is an appreciable response to placebo that confounds endpoint assessment. The aim of this study was to quantify contributors to the placebo response and its impact on liver fibrosis improvement. METHODS: Estimates of fibrosis improvement in placebo-treated participants were made using probabilistic simulation. Each simulated trial included 120 participants. Parameters considered in the model included sampling and observer variability, regression to the mean, and net fibrosis progression calibrated to reported trial outcomes. RESULTS: In large phase IIb and III trials, 22% of placebo-treated participants with fibrosis stage 2 or 3 NASH at baseline improved by at least 1 fibrosis stage with minimal net disease progression. Estimates of sampling and observer variability in simultaneous biopsy studies highlighted an imbalance where apparent fibrosis improvement was more likely than worsening. Using these estimates and known trial outcomes, net fibrosis progression was estimated at 0.05 stages per year. Simulations of the placebo response rate showed a rate of 22% with 80% of trials falling between 15 and 30%, in keeping with trials reported to date. Additional increases in observer variability further increased the placebo response. CONCLUSIONS: The analyses presented simply define the placebo response in liver fibrosis in trials in NASH in terms of sampling and observer variability, regression to the mean, and fibrosis progression. Factors relating to liver biopsy are largely unmodifiable, and the variation in placebo response rates, both simulated and observed, challenges the role of biopsy in trial endpoint assessment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rowe IA, Parker R. The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained. Clin Gastroenterol Hepatol. 2021. PMID: 34091047. doi:10.1016/j.cgh.2021.05.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。